More than 60 oncologists, data scientists, pharma/biotech industry leaders, patient advocates, health science research investigators, and regulators representing myriad esteemed institutions convened in Bethesda, Md., on August 8 for Project Data Sphere, LLC’s (PDS) sixth symposium co-sponsored with the U.S. Food and Drug Administration (FDA). With the goal of accelerating new options for small cell lung cancer patients (SCLC) in a stagnant treatment landscape, PDS is collaborating with the FDA on the development of an external control arm for SCLC clinical trials. This would enable patients to be enrolled directly into a trial’s new drug investigational arm, which ultimately would reduce the number of patients per trial as well as the cost and time of discovery for new treatment options. The daylong event featured a combination of individual and panel presentations and lively discussions